Tech Company Financing Transactions
Exicure Funding Round
AbbVie Biotech Ventures and private investors invested in a Series B funding round for Exicure. The round was announced on 12/21/2011.
Transaction Overview
Company Name
Announced On
12/21/2011
Transaction Type
Venture Equity
Amount
Unknown
Round
Series B
Investors
Proceeds Purpose
This financing underscores the highly unique benefits of the SNA platform and will accelerate our efforts to developit to its full potential -- supporting therapies for multiple diseases.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
8045 Lamon Ave. 410
Skokie, IL 60077
USA
Skokie, IL 60077
USA
Phone
Website
Email Address
Not Recorded
Overview
AuraSense Therapeutics is a development-stage biotechnology company founded to pursue the unique commercial potential of Spherical Nucleic Acid (SNA) constructs. These novel constructs possess unparalleled biocompatibility and versatility as therapeutics.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Giljohann
Chief Financial Officer
David Snyder
Chief Operating Officer
Matthias Schroff
Browse more venture capital transactions:
Prev: 12/21/2011: Presidio Pharmaceuticals venture capital transaction
Next: 12/21/2011: Stion venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on tech company VC transactions. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs